Last reviewed · How we verify
NCT03731962
Using Preprocedural Urine NMR(Nuclear Magnetic Resonance) -Based Metabolomics Analysis
NA trial testing Coronary Angiography in Contrast-induced Nephropathy in 100 participants. Completed in 1 November 2018.
1 September 2018
Quick facts
| Lead sponsor | Shahid Beheshti University of Medical Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 1 August 2018 |
| Primary completion | 1 September 2018 |
| Estimated completion | 1 November 2018 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Coronary Angiography
Conditions studied
- Contrast-induced Nephropathy — all drugs for Contrast-induced Nephropathy →
- Coronary Angiography — all drugs for Coronary Angiography →
Sponsor
Shahid Beheshti University of Medical Sciences
Who can join
18 and older, any sex, with Contrast-induced Nephropathy or Coronary Angiography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The use of coronary intervention has increased over the last decade. Contrast induced nephropathy (CIN) that develops as a result of procedures using intravenous or intra arterial contrast enhancement, or other diagnostic procedures, has been reported to be the third leading cause of acute renal failure in hospitalized patients. It has been hypothesized that this occurs as a result of direct toxicity, oxidative stress, and ischemic injury. Numerous studies have evaluated the incidence of CIN in patients undergoing angiography. There are limited studies in the acute care setting. Therefore, a tool that could identify early risk factors for CIN would be valuable for patient care. Metabolomic profiling is the identification of small molecule metabolites that are altered in response to injury. We hypothetize that urine metabolomic profiles may differ in patients before and after contrast administration coronary intervention.We hypothesized that metabolomic profiles will differ between those patients who develop CIN and those who do not after contrast administration. In addition we believe that metabolomics profiles prior to angiography may identify subjects who will go on to develop CIN and are therefore at higher risk.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03731962
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Coronary Angiography
Trials testing the same drug.
- NCT07076771 — Serum Testosterone Level on Angiographic Complexity of Coronary Lesions in Premature Ischemic Egyptian Males · recruiting
- NCT07076732 — Beyond Platelet Indices, WBC-to-MPV Ratio in Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA) Corre · completed
- NCT05075590 — Coronary Access After Supra-Annular THV Implantation · NA · unknown
- NCT04431661 — CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients · terminated
- NCT04656366 — Results of Coronary Angiography Rafter CABG: Comparison Between No-touch and Conventional Vein Graft · unknown
Other recruiting trials for Contrast-induced Nephropathy
Currently open trials in the same condition.
- NCT07459413 — Oral vs. Intravenous Hydration to Prevent Contrast-Associated Acute Kidney Injury in the ED · NA · recruiting
- NCT06418542 — Contrast Nephropathy Associated FFA · Phase 4 · active not recruiting
- NCT04606056 — Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans · active not recruiting
- NCT05283512 — Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanc · NA · recruiting
Other Shahid Beheshti University of Medical Sciences trials
Trials by the same sponsor.
- NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
- NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
- NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
- NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
- NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03731962 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
- Last refreshed: 7 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03731962.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing